Korea Investment CORP Has $34.56 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Korea Investment CORP lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 61,457 shares of the biopharmaceutical company’s stock after acquiring an additional 5,181 shares during the period. Korea Investment CORP’s holdings in Regeneron Pharmaceuticals were worth $34,555,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Dodge & Cox lifted its stake in Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after acquiring an additional 1,502,198 shares during the last quarter. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $628,151,000. Loomis Sayles & Co. L P increased its stake in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after purchasing an additional 305,089 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 26.5% in the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock valued at $564,808,000 after purchasing an additional 225,078 shares during the period. Finally, Federated Hermes Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 491.2% in the 2nd quarter. Federated Hermes Inc. now owns 245,587 shares of the biopharmaceutical company’s stock valued at $128,933,000 after purchasing an additional 204,045 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 5,274 shares of company stock valued at $4,142,738. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 2.9%

Regeneron Pharmaceuticals stock opened at $781.60 on Tuesday. The company’s 50-day moving average price is $770.83 and its two-hundred day moving average price is $690.73. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock has a market cap of $82.63 billion, a P/E ratio of 18.81, a P/E/G ratio of 2.04 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company posted $12.07 earnings per share. The business’s revenue was up 2.5% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were paid a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Analyst Ratings Changes

A number of equities analysts recently commented on REGN shares. Scotiabank lifted their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Cantor Fitzgerald upped their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Finally, BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.